Most DHEA advice reduces to “take some and see.” That is not a dosing strategy, it is a shrug with a bottle attached. This piece runs the actual dose figures through a rubric: sample size, whether the endpoint is a hormone level or a real clinical outcome, whether a finding replicates across more than one study, and what the same dose costs in side effects. Four criteria, applied the same way to every use case, no exceptions for popularity. DHEA has a documented dose-response relationship, which means the milligram figure is not decoration. It is the whole story, if you read it correctly.
The five numbers that anchor everything
Before any grading, the raw figures, each tied to its source and nothing else:
- 50 mg per day. The dose in the strongest positive adrenal insufficiency trial [3], and the dose flagged in the largest meta-analysis on hormonal effects [4].
- About 7 pg/mL. The average rise in estradiol that 50 mg/day produced in women, pooled across randomized trials, weighted mean difference roughly 7.02 pg/mL [4]. This is the number that confirms the compound is doing something measurable, not sitting inert.
- 106 patients, 12 months. Size and duration of the adrenal insufficiency trial behind the 50 mg figure [3].
- 1,200+ women, 28 trials. The scope of the Cochrane review that found no quality-of-life benefit and flagged androgenic side effects [2].
- Zero. The performance benefit the NIH review attributes to DHEA for exercise or athletic performance [1].
Five numbers, one shape: a well-defined studied dose, a measurable hormonal effect at that dose, and a narrow clinical benefit. The rest of this piece is the scoring behind that shape.
The rubric
Four criteria, applied identically to each use case:
- Sample size , small single studies score lower than pooled or larger trials.
- Endpoint type , a hormone-level change (mechanism) scores lower than a real clinical outcome (benefit), unless both are present.
- Replication , one trial is a data point, a meta-analysis is a pattern.
- Side-effect load at the effective dose , a benefit that arrives with a documented cost gets marked down accordingly.
No use case gets bonus points for being popular. The table below is the result.
The scored field
| Use case | Studied dose | Sample size | Endpoint type | Replicated? | Side-effect cost | Grade |
|---|---|---|---|---|---|---|
| Adrenal insufficiency | 50 mg/day | 106 patients, 12 months | Clinical outcome (lean mass, bone, one QoL subscale) | Single RCT [3] | Not separately quantified | Moderate |
| Raising estradiol (women) | 50 mg/day | 1,223 participants, 21 arms | Hormone level, not outcome | Meta-analysis [4] | Larger effect = larger androgenic risk [2] | Strong for the mechanism, not the benefit |
| Menopausal quality of life | Varied | 1,200+ women, 28 trials | Clinical outcome | Cochrane review [2] | Androgenic effects present, mainly acne | Negative |
| Sexual function (women) | Varied | Same 28-trial pool | Clinical outcome | Cochrane review [2] | Same as above | Weak, possible small effect only |
| Dyspareunia (vaginal symptom) | Approved insert dose | FDA approval basis | Clinical outcome | Single approved indication [5] | Localized, narrow use | Strong, but narrow |
| Anti-aging, energy, performance | Varied | Minimal | Neither hormone data nor outcome data supports it | Not replicated [1] | N/A, no benefit to weigh against a cost | None |
Read the table by column, not just by grade. The estradiol line has the best sample size and the strongest replication of anything on this list, and it still scores “strong for the mechanism, not the benefit,” because a 7 pg/mL hormone shift is not itself a health outcome. That gap, high confidence in what the dose does hormonally, low confidence in what it does for a person’s actual complaint, is the single most important thing this table shows.
Why 50 mg keeps showing up, scored honestly
It is not coincidence that 50 mg/day appears in both the strongest outcome trial and the largest mechanism study. In the trial, 106 people with primary adrenal insufficiency took 50 mg DHEA or placebo for a year [3]. The DHEA group gained lean mass, stopped losing bone at the femoral neck, and improved on one QoL subscale. Scored against the rubric: decent sample size, a real clinical outcome, single trial (not yet replicated), and no separately quantified side-effect tally. That earns “moderate,” not “strong,” because a single 106-person trial is a data point, however clean.
The meta-analysis scores differently. Across 21 arms and 1,223 participants, 50 mg raised estradiol by roughly 7.02 pg/mL on average, with bigger effects in women 60 and older and at 26+ weeks of use [4]. Large sample, pooled data, clear pattern. That’s a “strong” score on three of four criteria. It fails the fourth: the endpoint is a hormone level, not a symptom or a diagnosis improving. Two studies, same dose, different grades, and the difference in grade is entirely about what was actually measured.
The practical caveat: because 50 mg reliably raises estradiol by a measurable amount, it is functioning as a pharmacological dose with real downstream effects. Whether that shift helps or harms a given person depends on that person, not on the number itself. A dose earning a good grade in a study is not the same as a dose earning a good grade for you specifically.
Scoring the side-effect side of the ledger
A dosing grade that only counts benefit is an incomplete grade. The Cochrane review of 1,200+ women found some evidence of androgenic side effects, mostly acne [2]. The estradiol meta-analysis supplies the mechanism behind that: the hormonal shift scales with dose and with duration [4]. Put the two studies side by side and a rule falls out cleanly: bigger doses and longer courses produce bigger hormonal changes, and bigger hormonal changes are what drive the androgenic effects on record.
That rule caps the grade of “more DHEA” as a strategy. More is not automatically a better score, because the quality-of-life benefit was already absent before dose gets pushed higher [2]. A rubric that rewards effect size without penalizing cost is a bad rubric. This one doesn’t, and neither should anyone’s personal dosing decision.
The number the supplement aisle refuses to publish
Every grade above assumes the milligram figure on the label is real. That assumption fails at the pharmacy-adjacent supplement shelf. Over-the-counter DHEA is regulated as food, not drug, so the stated content rests on the manufacturer’s word rather than premarket verification. Score that against the rubric and it’s disqualifying: you cannot assign a grade to a dose you cannot confirm.
One more entry for a specific population: DHEA is the most common prohibited anabolic agent found contaminating dietary supplements, and it’s banned in competitive sport at all times [1]. For a tested athlete, the relevant dose might be one the label never disclosed. No amount of careful rubric application fixes a number that was never accurately reported in the first place.
How to use a scorecard instead of a guess
Translating grades into a decision is a short checklist, not a philosophy.
Measure the baseline first. DHEA-S is the lab value that actually exists to test this. A decision anchored to a real number beats one anchored to the assumption that age-related decline equals deficiency. Most people reaching for DHEA have skipped this step entirely, which is the first item to fix, not the last.
Match the dose to a use case with an actual grade attached. The 50 mg figure earns its grade in the context of diagnosed adrenal insufficiency [3]. For dyspareunia, the better-scored option is the FDA-approved prasterone insert at its approved dose, not a self-selected oral milligram figure [5]. For anti-aging, energy, or performance, the grade is “none,” and no dose changes that outcome [1].
Track results against numbers, not impressions. Since DHEA produces measurable hormonal and side-effect shifts [2][4], the sound structure has a clinician set the dose against lab values and adjust on follow-up. Supervised-access platforms such as FormBlends are built around that loop specifically, pairing a clinician and a licensed pharmacy with a tracker app so dose and response get logged as data rather than recalled from memory. Nothing here is for sale on this page; it’s a description of how a supervised process is supposed to work.
Final tally
Score DHEA dosing the way this piece has, and the picture holds together. The reference dose is 50 mg/day, drawn from the best available trial and the largest meta-analysis [3][4]. At that dose, the hormonal effect is real and quantified, roughly a 7 pg/mL rise in estradiol in women [4], which is the reason the compound earns supervision rather than a shrug. The clinical benefit at that dose is narrow: adrenal insufficiency, a possible small effect on sexual function, one approved local indication [2][3][5]. For the reasons people actually buy it, energy, anti-aging, performance, the score is zero [1].
No single dose here is a universal recommendation. What the rubric hands you instead is a reference point, a measured effect size, and a documented warning that bigger doses and longer courses buy bigger hormonal shifts without buying bigger benefit [4]. Measure first, match the dose to a use case that has actually earned its grade, and track the result under supervision. That’s the whole method.
Questions worth asking before you dose anything
Why does 50 mg keep coming up as the DHEA reference dose?
Because it’s the dose behind both of the two best-scored data points available: the year-long adrenal insufficiency trial with the most defensible outcome numbers [3], and the largest estradiol meta-analysis with the clearest hormonal effect [4]. That double appearance is why it functions as a reference point. It is drawn from research populations, though, not handed down as a default for any one individual.
What does that 7 pg/mL figure actually score?
It measures the average estradiol rise that 50 mg/day produced in women across pooled randomized trials, a weighted mean difference of roughly 7.02 pg/mL [4]. Treat it less as a target to hit and more as proof of activity: it confirms DHEA does something measurable and dose-dependent, which is exactly why it belongs under lab monitoring rather than casual guesswork.
Does a higher dose score better?
No. Larger doses and longer durations produce larger hormonal shifts [4], and those larger shifts are what drive the documented androgenic effects, acne being the most common [2]. Since the quality-of-life benefit scored negative even before dose optimization [2], pushing the milligrams up mostly buys additional cost, not additional benefit.
Can the milligram number on an over-the-counter bottle be trusted?
Not on the same terms as a tested medication. Supplements are regulated as food, so label content reflects a manufacturer’s claim, not premarket verification, and the true amount is unconfirmed before sale [1]. Against a compound whose studied effects sit at a specific 50 mg figure [3][4], an unverified label disqualifies the whole calculation.
Should an athlete score DHEA as worth taking?
The performance data grades at zero regardless of dose [1]. Beyond that, DHEA is the most common prohibited anabolic agent found contaminating dietary supplements and is banned in sport year-round [1]. A tested athlete risks a positive result from a dose a label may never have disclosed. Bad trade on both sides of the ledger.
What’s the single most useful first move?
Get DHEA-S measured. It’s the lab value that actually exists for this purpose, and a decision built on a real number outscores one built on the assumption that an age-related decline is automatically a deficiency. Most people never take this step, which turns an open-ended guess into a data point a clinician can actually work with.
What side effects should realistically be expected?
Mostly androgenic ones: acne, oily skin, unwanted facial hair in women, irritability. These tend to surface when the dose runs high relative to someone’s actual baseline. Mild estrogenic effects also show up in some people. Symptoms generally ease when the dose comes down. Serious adverse events are rare across short-term studies, but data past the two-year mark is thin, so treat that as an open question rather than a settled one.
Does DHEA cause weight gain?
Not at typical doses, as far as the evidence goes. A few small trials have actually reported modest reductions in abdominal fat among older adults with low baseline DHEA. Individual response varies, and meaningful shifts in testosterone or estrogen could plausibly affect water retention or appetite in some people, but there isn’t strong evidence pointing either toward fat loss promises or firm weight-gain warnings.
Is it reasonable to just take DHEA on your own?
Depends entirely on who’s asking and why. In a healthy adult with already-normal DHEA, adding more is unlikely to help and can push levels into a range that produces side effects. Over-the-counter products add a second risk layer, since potency and purity aren’t federally regulated the way prescription drugs are. People with a genuine, bloodwork-confirmed need are better served through a physician-supervised compounding route, such as FormBlends, than by picking something off a shelf.
What is DHEA’s actual footprint in clinical practice?
Two areas carry real weight: adrenal insufficiency, where the body underproduces on its own, and vaginal atrophy in postmenopausal women, where a low-dose insert carries FDA approval. Beyond those two, researchers have looked at bone density, mood, and cognition in older adults with documented deficiency, with mixed results from mostly small trials. Most physicians stay inside the approved lanes for exactly that reason.
References
- Dietary Supplements for Exercise and Athletic Performance: DHEA section, Health Professional Fact Sheet, NIH Office of Dietary Supplements. States that DHEA is sold over the counter as a supplement, that the body converts it to testosterone and estradiol, and that the minimal research on DHEA for exercise and athletic performance provides no evidence of benefit. https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/
- Scheffers CS, Armstrong S, Cantineau AEP, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;(1):CD011066. PMID: 25879093. Pooled 28 randomized trials in more than 1,200 women, concluding there is no evidence DHEA improves quality of life, some evidence of androgenic side effects (mainly acne), unclear effect on menopausal symptoms, and a possible small improvement in sexual function. https://pubmed.ncbi.nlm.nih.gov/25879093/
- Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93(2):400-409. PMID: 18000094. In 106 patients with primary adrenal insufficiency taking 50 mg DHEA or placebo for 12 months, DHEA improved one quality-of-life subscale, increased lean body mass, and reversed bone loss at the femoral neck, without changing fat mass, fatigue, or cognition.
- The effect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: a dose-response and meta-analysis of randomized clinical trials. Steroids. 2021;174:108889. PMID: 34246664. Across 21 arms and 1,223 participants, DHEA significantly increased estradiol (weighted mean difference about 7.02 pg/mL), with larger effects in women aged 60 and older, at 50 mg/day, and over durations of 26 weeks or more.
- INTRAROSA (prasterone) vaginal insert, U.S. Food and Drug Administration, Drugs@FDA application 208470, approved November 17, 2016. The active ingredient prasterone is dehydroepiandrosterone (DHEA); the product is indicated only for moderate to severe dyspareunia (pain during intercourse) due to vulvar and vaginal atrophy in postmenopausal women.
